(Q43042833)

12 November 2017

Is gemcitabine cost effective in cancer treatment? (English)

1 reference

12 November 2017

9

1 reference

12 November 2017

Luca Toschi

1

1 reference

12 November 2017

Giovanna Finocchiaro

2

1 reference

12 November 2017

Giovanni Luca Ceresoli

3

1 reference

12 November 2017

Paolo Andrea Zucali

4

1 reference

12 November 2017

Raffaele Cavina

5

1 reference

12 November 2017

Isabella Garassino

6

1 reference

12 November 2017

Fabio De Vincenzo

7

1 reference

12 November 2017

Armando Santoro

8

1 reference

12 November 2017

1 June 2007

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

12 November 2017

1 reference

12 November 2017

7

1 reference

12 November 2017

3

1 reference

12 November 2017

239-249

1 reference

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

12 November 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical T

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Chemotherapy prolongs survival in inoperable pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Treatment of locally advanced pancreatic carcinoma in Sweden. A health economic comparison of palliative treatment with best supportive care versus palliative treatment with gemcitabine in combination with best supportive care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Treatment cost of pancreatic cancer in Japan: analysis of the difference after the introduction of gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Single-agent gemcitabine is active in previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.239

21 January 2018

Identifiers

DOI

10.1586/14737167.7.3.239

1 reference

12 November 2017

1 reference